Under the Medicines Australia agreement, PBAC considered an immediate change to the discount rate with implementation planned through updated guidelines from July 2022. That change never arrived. The committee opposed any reduction. Surely that prejudices any role for the committee in the new review. Yes, a new review.
Every new working group and every consultation squeezes more life out of reform, like a lemon wrung to its rind
September 4, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News
